StockNews.AI
TMCI
StockNews.AI
78 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Treace Medical Concepts, Inc. - TMCI

1. Pomerantz LLP is investigating Treace Medical for possible securities fraud. 2. TMCI lowered its 2024 revenue guidance significantly after market hours. 3. The stock price fell by nearly 63%, closing at $4.17 on May 8, 2024. 4. Increased competition hurt TMCI’s Lapiplasty growth potential. 5. Investigations like this can lead to further legal challenges and loss of investor confidence.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant revenue downgrade and subsequent legal investigation create high uncertainty, reminiscent of past stock downtrends from corporate litigation concerns.

How important is it?

The potential for legal action over securities fraud and the revenue revision indicate significant risks that may influence TMCI's perception and price.

Why Short Term?

Immediate legal investigations and possible shareholder lawsuits typically affect stock prices quickly, similar to past securities fraud cases.

Related Companies

MDTSNNZBH
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Treace Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] After market hours on May 7, 2024, Treace Medical issued a press release reporting, among other things, that it lowered its full-year 2024 revenue guidance from between $220 million and $225 million to between $201 million and $211 million.  During the associated earnings call the same day, the Company revealed competition from minimally invasive osteotomy and Lapiplasty “knockoffs” created headwinds for Lapiplasty growth. On this news, the Company’s stock price fell $6.95, or nearly 63%, to close at $4.17 per share on May 8, 2024, on unusually high trading volume. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News